NCT07217496 2026-03-17N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerUniversity of California, San FranciscoPhase 1 Withdrawn
NCT04290546 2026-02-27CIML NK Cell in Head & Neck CancerDana-Farber Cancer InstitutePhase 1 Completed11 enrolled
NCT02523469 2026-02-17ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung CancerMedical University of South CarolinaPhase 1/2 Completed67 enrolled 12 charts
NCT07355205 2026-01-21FLINNWashington University School of MedicinePhase 2 Not yet recruiting26 enrolled